Figure 2.

The influence of the AAPs aripiprazole (a), risperidone (b), and amisulpride (c) and negative control treatments lorazepam (d), modafinil (e), and valproate (f) on sensorimotor gating expressed as percent PPI. Aripiprazole increased PPI in the low-gating subgroup and decreased PPI in the high-gating subgroup. Risperidone and amisulpride did not significantly influence sensorimotor gating. Whereas valproate did not significantly modulate PPI, lorazepam and modafinil attenuated sensorimotor gating independently of high- and low-gating group. Differences in placebo gating within one cohort originate from the exclusion of invalid data sets in a nonpairwise manner. *Significant difference between active drug and placebo. Error bars refer to SEM.